Biochemistry, Genetics and Molecular Biology
Blood Plasma
75%
Cancer Cell
66%
Centrifugation
45%
Cytokine
40%
Enzyme
37%
K562 Cells
33%
Amino Acids
33%
DNA Sequence
33%
STAT5
33%
Catenin
33%
Signal Transduction
33%
Transcription
33%
STAT1
33%
Metabolic Pathway
33%
Nuclease
33%
Interferon
33%
Metabolomics
33%
DNA Extraction
33%
COX-2 Inhibitor
33%
Heparin
26%
Metabolite
25%
Transcriptomics
25%
Isoform
22%
Fluorescence Spectroscopy
22%
Cyclin D1
19%
Genetics
16%
Glucocerebrosidase
16%
Pseudogene
16%
Sequence Homology
16%
Amplicon
16%
Phosphoribosyltransferase
16%
Coding Region
16%
Prevalence
16%
Genetic Risk
16%
Glucosylceramidase
16%
Celecoxib
16%
Cyclooxygenase
16%
Interleukin 8
13%
Turnaround Time
13%
Gene Expression
11%
C-Terminus
11%
STAT3
11%
16S Ribosomal RNA
11%
Transactivation
11%
Drug Resistance
11%
Real-Time Polymerase Chain Reaction
11%
Messenger RNA
11%
Metagenomics
11%
Supernatant
11%
Transcription Initiation
11%
Pharmacology, Toxicology and Pharmaceutical Science
Parkinson's Disease
100%
Malignant Neoplasm
44%
Tumor Necrosis Factor
38%
Antiinfective Agent
33%
Xanthine
33%
COX-2 Inhibitor
33%
RNA 16S
33%
Curcumin
33%
Natural Product
33%
Amino Acid
33%
Cytokine
33%
Randomized Controlled Trial
33%
Immunocompromised Patient
33%
Immunomodulating Agent
33%
Comorbidity
33%
Observational Study
33%
Disease
28%
Heparin
26%
Cardiovascular Disease
19%
Celecoxib
16%
Cyclooxygenase 2
16%
Secondary Infection
14%
Interferon
14%
Ethylenediaminetetraacetic Acid
13%
Interleukin 8
13%
Biological Marker
12%
Leukemia
11%
Antiapoptotic
11%
Drug Resistance
11%
Inflammatory Disease
11%
DNA B
11%
Proteasome
11%
Phosphotransferase
11%
Cytotoxicity
11%
Myelodysplastic Syndrome
9%
Disease Exacerbation
8%
Hallucination
8%
Hypoxanthine Phosphoribosyltransferase
7%
Glutamic Acid
6%
Interleukin 16
6%
CD40 Ligand
6%
Enzyme-Linked Immunosorbent Assay
6%
Etoposide
5%
Nimesulide
5%
Prostaglandin E
5%
NS-398
5%
Enzyme Inhibitor
5%
Cancer Model
5%
Hydrogen Peroxide
5%
Medicine and Dentistry
Parkinson's Disease
100%
Randomized Controlled Trial
100%
COVID-19
100%
Care Group
38%
Gut Microbiome
33%
Mild Cognitive Impairment
33%
microRNA
33%
Progressive Supranuclear Palsy
33%
Cardiovascular System
33%
Observational Study
33%
Anakinra
33%
Comorbidity
33%
Metabolomics
33%
Immunomodulating Agent
33%
Immunocompromised Patient
33%
Meta-Analysis
33%
Disease
24%
Cardiovascular Disease
19%
Secondary Infection
14%
Hazard Ratio
11%
Attributable Risk
11%
Unified Parkinson's Disease Rating Scale
9%
Myelodysplastic Syndrome
9%
Odds Ratio
8%
Hallucination
8%
Disease Exacerbation
8%
Biological Marker
8%
Diagnosis
8%
Noninvasive Ventilation
8%
Interleukin 6
7%
Adverse Event
5%
Assisted Ventilation
5%
Cytokine
5%
